Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 9/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14946793 | 0.78 | KIF11 (0.41) | KIF11HDAC3HDAC1HDAC2KCNH2 | |
| SCHEMBL12075610 | 0.74 | HDAC3 (0.44) | KIF11HDAC3HDAC1HDAC2KCNH2 | |
| SCHEMBL18409776 | 0.74 | KCNN4 (0.49) | KIF11HDAC3HDAC1HDAC2KCNH2 | |
| SCHEMBL3496480 | 0.73 | KIF11 (0.54) | KIF11KCNH2KMT2ALMNAHTT | |
| SCHEMBL15517407 | 0.69 | KIF11 (0.56) | KIF11KCNH2MEN1KMT2ALMNA | |
| Anisole SCHEMBL9360868 | 0.69 | CA4 (0.58) | HDAC3HDAC1HDAC2KCNH2ALDH1A1 | |
| SCHEMBL10877618 | 0.68 | KIF11 (0.73) | KIF11KCNH2ALDH1A1MEN1KMT2A | |
| SCHEMBL18902445 | 0.68 | KIF11 (0.47) | KIF11KCNH2ALDH1A1KMT2ALMNA | |
| SCHEMBL7706703 | 0.68 | KIF11 (0.73) | KIF11KCNH2ALDH1A1MEN1KMT2A | |
| SCHEMBL8403280 | 0.68 | KIF11 (0.48) | KIF11KCNH2MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220751-A1 | Non-Fluorescent Quencher Compounds and Biomolecular Assays | Life Technologies Corporation (US) | 2012-08-30 | — | — | US | disclosed |
| US-20110245462-A1 | Non-Fluorescent Quencher Compounds and Biomolecular Assays | Life Technologies Corporation (US) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245462-A1 | Non-Fluorescent Quencher Compounds and Biomolecular Assays | DNTT, PNP, NT5C2 | KIF11 4673/4885HDAC3 1654/4885HDAC1 4147/4885 |
| US-20120220751-A1 | Non-Fluorescent Quencher Compounds and Biomolecular Assays | DNTT, PNP, NT5C2 | KIF11 4673/4885HDAC3 1654/4885HDAC1 4147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.